Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$24.4 million.

  • NewAmsterdam Pharma's Net Cash Flow fell 9467.21% to -$24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.1 million, marking a year-over-year increase of 13322.45%. This contributed to the annual value of $438.1 million for FY2024, which is 43106.25% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its Net Cash Flow stood at -$24.4 million for Q3 2025, which was down 9467.21% from -$193.4 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Net Cash Flow ranged from a high of $357.0 million in Q4 2024 and a low of -$193.4 million during Q2 2025
  • Over the past 3 years, NewAmsterdam Pharma's median Net Cash Flow value was -$28.3 million (recorded in 2023), while the average stood at $8.4 million.
  • Per our database at Business Quant, NewAmsterdam Pharma's Net Cash Flow surged by 117915.17% in 2024 and then plummeted by 29043.41% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Net Cash Flow (Quarter) stood at -$33.1 million in 2023, then soared by 1179.15% to $357.0 million in 2024, then plummeted by 106.83% to -$24.4 million in 2025.
  • Its Net Cash Flow was -$24.4 million in Q3 2025, compared to -$193.4 million in Q2 2025 and -$27.1 million in Q1 2025.